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background: Chronic obstructive pulmonary disease (COPD) is known to be associated with morbidity and mortality after open-chest cardiac 
surgery whereas limited data exist after transcatheter aortic valve implantation (TAVI). We aimed to determine the impact of COPD on Valve Academic 
Research Consortium (VARC)-defined outcomes in patients undergoing TAVI.
methods: We included all TAVI patients (symptomatic adults with severe aortic stenosis who were not candidates for surgical aortic valve 
replacement) enrolled from 01/2010 to 12/2011 in the French national TAVI registry “FRANCE 2”. Baseline characteristics and clinical outcomes 
were compared according to presence or not of concomitant COPD, defined as the presence of lung symptoms (e.g. progressive dyspnea, cough, 
wheezing, or sputum production) requiring long-term use of bronchodilators or steroids.
results: A total of 3933 consecutive patients underwent TAVI during the study period in 34 centers and were included; 895 (22.7%) had 
concomitant COPD, 3038 (77.3%) did not. There were no significant differences in procedural characteristics or 30-day VARC-defined outcomes 
between those with vs without COPD. Multivariate regression analysis showed COPD to be an independent predictor of 1-year mortality and 
combined efficacy end-point after adjustment for concomitant comorbidities, HR: 1.19 (95%CI 1.005-1.41; P = 0.03) and HR: 1.52 (95%CI 1.29-
1.79; P <0.001) respectively. The higher mortality at 1 year in COPD patients was related to cardiovascular deaths (COPD 10.0% vs. non-COPD 6.2%; 
P = 0.008). Subgroup analysis found that the effect of COPD on 1-year mortality was constant throughout different subgroups, especially the type of 
approach and the type of anesthesia.
conclusion: In this real-world registry, concomitant COPD in patients referred for TAVI characterizes a high-risk population. The excess in mortality 
is largely determined by a higher rate of cardiovascular deaths and exists regardless of the type of procedure performed and its results.
